Bruch

MyPrize Emerges Out of Stealth With $140 Million Total Enterprise Value, the Most Valuable Online Social Casino Pre-Launch

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Entertainment, Technology, Cryptocurrency, Internet, Casino, Gaming, CIO, Dragonfly, Friends, Entrepreneurship, FTX, General partnership, Kadoorie family, Galaxy Digital, Silicon, Jack Entertainment, XP, Justice, Former, Bruch, Multimedia, Blockchain.com

MyPrize transcends those boundaries, giving players and fans what they have been desperately craving: a unified, open platform that combines the best of both online gaming and streaming.

Key Points: 
  • MyPrize transcends those boundaries, giving players and fans what they have been desperately craving: a unified, open platform that combines the best of both online gaming and streaming.
  • MyPrize radically transforms the way players can interact and engage with their favorite streamers, friends, and online games together.
  • MyPrize brings scale and institutional credibility to this emerging industry as the most valuable venture-backed online social casino pre-launch.
  • "With the support of our investors and our team’s commitment to rapid product innovation, MyPrize will define the future of online social gaming."

OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.

Retrieved on: 
Tuesday, October 26, 2021
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Optical, Health, Clinical Trials, Safety, Bruch, AMD, VAC2, Surgeon, European Medicines Agency, U.S. Securities and Exchange Commission, Compte rendu, OCT, American Academy of Ophthalmology, RPE, Twitter, Gene, Lineage Cell Therapeutics, AAO, Therapy, David Geffen School of Medicine at UCLA, American Academy, Retinal pigment epithelium, History of the University of California, Los Angeles, Incidence, Blood, Severe cognitive impairment, Security (finance), Food, Infection, Injury, Ernest, Annual report, Company, EDT, Degenerative disease, Association, Department, Human embryonic stem cells clinical trials, Large-cell lung carcinoma, SEC, NYSE American, Geographic atrophy, Method, University, Cancer, TASE, FDA, Drusen, Forward-looking statement, Cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

, Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles.

Key Points: 
  • , Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles.
  • The American Academy of Ophthalmology is the worlds largest association of eye physicians and surgeons.
  • The mission of the American Academy of Ophthalmology is to protect sight and empower lives by serving as an advocate for patients and the public, leading ophthalmic education, and advancing the profession of ophthalmology.
  • The first 3 cohorts enrolled only legally blind patients with Best Corrected Visual Acuity (BCVA) of 20/200 or worse.

Outlook on the Choroidal Neovascularization Global Market to 2026 - by Product Type, Type of Diagnosis, Treatment Type, Application and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 30, 2021
Health, General Health, Retina, Adoption, OCT, Bruch, Histoplasmosis, Fluorescein angiography, Sterilization, FA, Choroid, Diagnosis, Retinal pigment epithelium, Angioid streaks, Solution, RPE, Distortion, Patient, Choroidal neovascularization, Angiography, PDT, Indocyanine green, Industry, ARMD, ICG, Growth, Prevalence, Disease, Risk, VEGF, COVID-19, Research, CNV, Blood, R, Investment, Coronavirus, Pharmaceutical industry, Potash

Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision.

Key Points: 
  • Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision.
  • How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global choroidal neovascularization market?
  • What is the structure of the global choroidal neovascularization market and who are the key players?

Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Retrieved on: 
Thursday, September 30, 2021
Research, Surgery, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Optical, Science, OCT, Therapy, Geographic atrophy, Bruch, Cohort, Lineage Cell Therapeutics, AMD, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, University, Cell, Safety, VAC2, SEC, Food, Injury, European Medicines Agency, Multimedia, CEI, Infection, NYSE American, Incidence, Association, Retina, Degenerative disease, Severe cognitive impairment, Patient, Annual report, U.S. Securities and Exchange Commission, FDA, Cancer, Method, Company, LLC, Large-cell lung carcinoma, Forward-looking statement, Drusen, Time, Compte rendu, Diagnosis, Retinal pigment epithelium, Security (finance), RPE, Visual acuity, TASE, Trial of the century, NCSS, Blood, Treatment effect, Pharmaceutical industry, Dentistry, Medical imaging, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

This is an exciting time for the OpRegen program, the participating investigative sites, and for patients suffering from dry AMD.

Key Points: 
  • This is an exciting time for the OpRegen program, the participating investigative sites, and for patients suffering from dry AMD.
  • The efficacy findings presented today are both statistically significant as well as clinically important, stated Christopher D. Riemann, M.D.
  • Prior clinical data readouts were mostly descriptive and lacked enough patients and post-treatment follow-up to allow for detailed statistical analyses.
  • For more information on the Retina Society or its annual scientific meeting, please visit https://www.retinasociety.org/ or follow the association on Twitter @RetinaSociety .

Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Lineage Cell Therapeutics, OCT, Degenerative disease, Infection, Patient, Retinal pigment epithelium, Institute, Adult, Large-cell lung carcinoma, Visual acuity, Blood, Cohort, Geographic atrophy, Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Forward-looking statement, Antibody, Health, NYSE American, Bruch, U.S. Securities and Exchange Commission, Annual report, Severe cognitive impairment, Growth, Central retinal artery occlusion, Cancer, RPE, Drusen, Optical coherence tomography, Food, Therapy, Security (finance), Cell, Incidence, FDA, VAC2, Retina, TASE, Injury, HIV disease progression rates, Safety, Human, SEC, Method, European Medicines Agency, Autumn, Technology, Company, Multimedia, History, Compte rendu, AMD, Atrophy, Pharmaceutical industry, Medical imaging, Silviculture, Dentistry, Hospital

While competing efforts are focused on reducing the growth rate of geographic atrophy, Lineage has reported several patients whose areas of atrophy have stabilized or reduced in size.

Key Points: 
  • While competing efforts are focused on reducing the growth rate of geographic atrophy, Lineage has reported several patients whose areas of atrophy have stabilized or reduced in size.
  • Importantly, all three of the patients exhibiting restoration had confirmed historic growth rate in these areas and these data have been collected using multiple imaging modalities.
  • We are extremely pleased that our data is moving in a positive direction with each interim update we provide.
  • We will continue to collect follow up data and work towards a meeting with FDA to discuss key aspects of our program.

Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Retrieved on: 
Monday, September 13, 2021
Health, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, European Medicines Agency, Drusen, Therapy, Association, Food, Incidence, Cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lineage Cell Therapeutics, Injury, University, Degenerative disease, VAC2, Clinical trial, Retina, TASE, Patient, Infection, Company, Retinal pigment epithelium, NYSE American, Bruch, Spinal cord injury, CEI, Severe cognitive impairment, Safety, Large-cell lung carcinoma, Blood, The Ritz-Carlton Hotel Company, Diagnosis, Cancer, AMD, Geographic atrophy, Method, RPE, Pharmaceutical industry, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.

Key Points: 
  • The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.
  • For more information on the Retina Society or its annual scientific meeting, please visit https://www.retinasociety.org/ or follow the association on Twitter @RetinaSociety .
  • The first 3 cohorts enrolled only legally blind patients with Best Corrected Visual Acuity (BCVA) of 20/200 or worse.
  • The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA).